Black Box Warnings and Drug Safety: Examining the Determinants and Timing of FDA Warning Labels
Author
Abstract
Suggested Citation
Note: EH LE
Download full text from publisher
References listed on IDEAS
- Berndt Ernst R. & Gottschalk Adrian H. B. & Philipson Tomas & Strobeck Matthew W., 2005.
"Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process,"
Forum for Health Economics & Policy, De Gruyter, vol. 8(1), pages 1-25, January.
- Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck, 2005. "Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process," NBER Chapters, in: Frontiers in Health Policy Research, Volume 8, National Bureau of Economic Research, Inc.
- Ernst R. Berndt & Adrian H. B. Gottschalk & Tomas Philipson & Matthew W. Strobeck, 2004. "Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process," NBER Working Papers 10822, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Ernst R. Berndt & Adrian H. B. Gottschalk & Matthew W. Strobeck, 2005.
"Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts,"
NBER Working Papers
11724, National Bureau of Economic Research, Inc.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Strobeck, Matthew W., 2005. "Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 199, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Mary K. Olson, 2002. "Pharmaceutical Policy Change and the Safety of New Drugs," Journal of Law and Economics, University of Chicago Press, vol. 45(S2), pages 615-642.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- W. Kip Viscusi & Richard J. Zeckhauser, 2015.
"Regulating Ambiguous Risks: The Less than Rational Regulation of Pharmaceuticals,"
The Journal of Legal Studies, University of Chicago Press, vol. 44(S2), pages 387-422.
- Viscusi, W. Kip & Zeckhauser, Richard, 2014. "Regulating Ambiguous Risks: The Less Than Rational Regulation of Pharmaceuticals," Working Paper Series rwp14-005, Harvard University, John F. Kennedy School of Government.
- Ali Shajarizadeh & Aidan Hollis, 2015. "Price‐cap Regulation, Uncertainty and the Price Evolution of New Pharmaceuticals," Health Economics, John Wiley & Sons, Ltd., vol. 24(8), pages 966-977, August.
- Tannista Banerjee & Arnab Nayak, 2017. "Why trash don’t pass? pharmaceutical licensing and safety performance of drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(1), pages 59-71, January.
- Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008.
"Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts,"
Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric, 2007. "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 217, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Olson, Mary K., 2008. "The risk we bear: The effects of review speed and industry user fees on new drug safety," Journal of Health Economics, Elsevier, vol. 27(2), pages 175-200, March.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Vernon, John A. & Golec, Joseph H. & Lutter, Randall & Nardinelli, Clark, 2009. "An exploratory study of FDA new drug review times, prescription drug user fee acts, and R&D spending," The Quarterly Review of Economics and Finance, Elsevier, vol. 49(4), pages 1260-1274, November.
- Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008.
"Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts,"
Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric, 2007. "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 217, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Olson, Mary K., 2008. "The risk we bear: The effects of review speed and industry user fees on new drug safety," Journal of Health Economics, Elsevier, vol. 27(2), pages 175-200, March.
- Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008.
"Pharmaceutical Industry, Drug Quality and Regulation: Evidence from US and Italy,"
NBER Working Papers
14567, National Bureau of Economic Research, Inc.
- Vincenzo Atella & Jay Bhattacharya & Lorenzo Carbonari, 2008. "Pharmaceutical industry, drug quality and regulation. Evidence from US and Italy," CEIS Research Paper 138, Tor Vergata University, CEIS, revised 16 Dec 2008.
- Abraham, John & Davis, Courtney, 2005. "A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): Implications for current regulatory thinking and policy," Social Science & Medicine, Elsevier, vol. 61(5), pages 881-892, September.
- W. David Bradford & Andrew N. Kleit, 2015. "Impact of FDA Actions, DTCA, and Public Information on the Market for Pain Medication," Health Economics, John Wiley & Sons, Ltd., vol. 24(7), pages 859-875, July.
- Samuel DeCanio, 2024. "Cost benefit analysis and the FDA: measuring the costs and benefits of drug approval under the PDUFA I-II, 1998–2005," Journal of Regulatory Economics, Springer, vol. 66(2), pages 174-180, December.
- Light, Donald W. & Lexchin, Joel R., 2021. "Pharmaceuticals as a market for “lemons”: Theory and practice," Social Science & Medicine, Elsevier, vol. 268(C).
- Henry Grabowski & Y. Richard Wang, 2008. "Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act," Journal of Law and Economics, University of Chicago Press, vol. 51(2), pages 377-406, May.
- Olson, Mary K., 2004. "Are novel drugs more risky for patients than less novel drugs?," Journal of Health Economics, Elsevier, vol. 23(6), pages 1135-1158, November.
- Chorniy, Anna & Bailey, James & Maloney, Michael & Civan, Abdulkadir, 2019. "Regulatory Review Time and Pharmaceutical R&D," Working Papers 06923, George Mason University, Mercatus Center.
- Sam Peltzman, 2010. "Regulation And The Natural Progress Of Opulence," Economic Affairs, Wiley Blackwell, vol. 30(2), pages 33-39, June.
- Andreas Schick & Kathleen L. Miller & Michael Lanthier & Gerald Dal Pan & Clark Nardinelli, 2017. "Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals," Drug Safety, Springer, vol. 40(6), pages 497-503, June.
- Guy David & Sara Markowitz & Seth Richards-Shubik, 2010.
"The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation,"
American Economic Journal: Economic Policy, American Economic Association, vol. 2(4), pages 1-25, November.
- Guy David & Sara Markowitz & Seth Richards, 2009. "The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation," NBER Working Papers 14634, National Bureau of Economic Research, Inc.
- Daniel B. Klein, 2008. "Colleagues, Where Is the Market Failure? Economists on the FDA," Econ Journal Watch, Econ Journal Watch, vol. 5(3), pages 316-348, September.
- Niklas Rudholm, 2004. "Approval times and the safety of new pharmaceuticals," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(4), pages 345-350, November.
- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
More about this item
JEL classification:
- I1 - Health, Education, and Welfare - - Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
- I28 - Health, Education, and Welfare - - Education - - - Government Policy
- K2 - Law and Economics - - Regulation and Business Law
- K23 - Law and Economics - - Regulation and Business Law - - - Regulated Industries and Administrative Law
- K32 - Law and Economics - - Other Substantive Areas of Law - - - Energy, Environmental, Health, and Safety Law
NEP fields
This paper has been announced in the following NEP Reports:- NEP-HEA-2007-01-13 (Health Economics)
- NEP-LAW-2007-01-13 (Law and Economics)
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nbr:nberwo:12803. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: the person in charge (email available below). General contact details of provider: https://edirc.repec.org/data/nberrus.html .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.